文献速递疼痛医学区域麻醉与超声

宫颈段鞘内镇痛治疗癌痛:综合癌症中心12年随访研究

Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study in a comprehensive cancer center.
PubMed 文献 · Reg Anesth Pain Med · 2024-10-08

结果显示植入后1周、1个月、2个月和3个月疼痛评分较基线显著降低(p<0.01),93%的患者在植入后第一周疼痛评分降低50%。结论认为长期宫颈段鞘内多药治疗适合且安全。

要点

  • 宫颈段鞘内多药镇痛可显著降低难治性癌痛患者疼痛评分。
  • 植入后第一周93%患者疼痛评分降低50%。
  • 疼痛缓解在1周、1个月、2个月和3个月均具统计学显著性。

核心结论

  • 长期经宫颈段鞘内导管多药联合治疗癌痛在研究人群中适合且安全。
  • 治疗可带来具有临床和统计学意义的疼痛缓解。

研究设计与样本

  • 单中心回顾性随访研究,纳入2010年1月至2022年12月所有接受鞘内治疗并置入宫颈段导管的患者。
  • 疼痛评估采用数字评定量表(NRS),疼痛评分比较采用Wilcoxon符号秩检验。

主要发现

  • 植入患者存在严重疼痛,术前平均最大NRS评分为8.02±0.24,尽管平均每日口服吗啡当量为562.56±127.72 mg。
  • 鞘内治疗开始后平均生存时间为208.48±67天。
  • 与初始疼痛评分相比,鞘内药物输注系统在1周、1个月、2个月和3个月时均提供显著统计学差异的疼痛缓解(p<0.01)。
  • 93%的病例在鞘内植入后第一周内初始疼痛水平降低50%。

临床怎么用

  • 对于口服大剂量阿片类药物仍疼痛严重的难治性癌痛患者,可考虑宫颈段鞘内多药联合镇痛治疗。
  • 治疗后需通过日间病房访视和电话进行至少每月随访以评估疼痛评分。

局限性

  • 本研究为单中心回顾性随访研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intrathecal analgesia plays a key role for patients suffering refractory cancer pain. Nevertheless, intrathecal drug delivery systems (IDDS), requiring a cervical catheter tip implantation, have been poorly described in medical literature. AIMS: A monocentric retrospective follow-up study was designed to evaluate results of cervical IDDS for cancer pain. PATIENTS AND METHODS: From January 2010 to December 2022, all intrathecal-treated patients were prescribed a combined intrathecal analgesics regimen through a catheter placed in the cervical vertebral canal. Post-implant assessment of pain was determined using a numeric rating scale (NRS). Patients were followed via day-hospital visits and telephone calls at least monthly. Pain scores were compared using the Wilcoxon's signed rank test. RESULTS: Ninety-eight patients were included in this study; all received intrathecal treatments. Implanted patients suffered from severe pain (mean presurgical maximum numerical rating score 8.02±0.24 despite a mean 562.56±127.72 mg of oral morphine equivalent daily dose). Mean survival time after intrathecal treatment start was 208.48±67 days. Intrathecal drug delivery systems provided pain relief compared with initial pain score with a significant statistical difference after 1 week, 1 month, 2 and 3 months (p<0.01). A 50% reduction in initial pain level was achieved in 93% of cases during the first week of intrathecal implant. CONCLUSIONS: Results suggest that long-term intrathecal treatment using a multidrug regimen for cancer-related pain through cervical intrathecal catheters was suitable and safe in our study population. We demonstrated a clinically and statistically significant pain reduction in patients using mainly a percutaneous lumbar approach.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Dupoiron D, Bienfait F, Carvajal G, et al. Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study in a comprehensive cancer center. Reg Anesth Pain Med. 2024. PMID: 37973378. doi:10.1136/rapm-2023-104961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。